证券代码：688056 证券简称：莱伯泰科 公告编号：2025-036 关于公司持股 5%以上股东协议转让部分股份 暨权益变动的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 10 月 20 日，北京莱伯泰科仪器股份有限公司（以下简称"莱伯 泰科"或"公司"或"目标公司"）持股 5%以上股东 LabTech Holdings, Inc. （以下简称"LabTech Holdings"或"转让方"）与青岛市创新投资有限公司（以 下简称"青岛创新投资"或"受让方"）共同签署了《股份转让协议》，LabTech Holdings 拟以 27.50 元/股的价格向青岛创新投资转让其持有的公司无限售流通 股 4,145,454 股，占公司股份总数的 6.15%。本次协议转让完成后，青岛创新投 资将持有公司股份 4,145,454 股，占公司股份总数的 6.15%，成为公司持股 5% 以上股东。 本次协议转让不会导致公司控股股东、实际控制人发生变更，不触及要 约收购，不会对公司治理结构及持 ...

格隆汇10月20日丨莱伯泰科(688056.SH)公布，2025年10月20日，公司持股5%以上股东LabTech Holdings 与青岛创新投资共同签署了《股份转让协议》，LabTech Holdings拟以27.50元/股的价格向青岛创新投资 转让其持有的公司无限售流通股414.55万股，占公司股份总数的6.15%。 ...

人民财讯10月20日电，莱伯泰科(688056)10月20日公告，股东LabTech Holdings,Inc.(简称"转让方")与青 岛市创新投资有限公司(简称"青岛创新投资")共同签署了《股份转让协议》，转让方拟以27.50元/股的 价格向青岛创新投资转让其持有的公司无限售流通股414.55万股，占公司股份总数的6.15%。 ...

Core Insights - The chairman of LabTech emphasizes the critical role of scientific instruments in achieving scientific breakthroughs and becoming a technology powerhouse [2] - LabTech, as one of the first companies listed on the Sci-Tech Innovation Board in China's scientific instrument industry, focuses on increasing market share in analytical instruments and providing comprehensive solutions across the entire product chain [2][3] - The scientific instrument industry is undergoing a transformation towards automation and intelligence, with Chinese brands shifting from a defensive to an offensive strategy [2][5] Company Development - Initially, LabTech aimed to survive by offering basic products that were easy to use and of high quality, such as heating plates and cooling systems [3] - Collaborations with industry giants like Siemens helped LabTech quickly establish a market presence and reduce sales costs [3] - LabTech identified an opportunity in automating sample preparation processes, becoming the first company to systematically address this area in the industry [3][4] Strategic Focus - The company aims to lead the industry by targeting high-end fields such as semiconductors, leveraging its expertise in mass spectrometry [4] - LabTech is transitioning from a sample preparation expert to a "full-chain intelligent manufacturer," providing integrated solutions from sample processing to analysis [5] - The rapid development of new fields, such as semiconductor testing, presents significant opportunities for growth, as traditional market boundaries are being broken [6] International Market Strategy - LabTech's strategy for entering international markets focuses on exploiting gaps left by international brands in sample preparation and analysis [7] - The company has established R&D and production centers abroad, aiming for a localized operational system that encompasses R&D, production, and service [8] - LabTech believes that within 5 to 10 years, Chinese brands will capture a significant share of the global high-end detection instrument market, with aspirations to become a leading mass spectrometry brand [8]

Core Viewpoint - The article discusses the critical role of fundraising investment projects (募投项目) in corporate development, highlighting the delays and terminations faced by several companies in the industry due to various factors [1][3]. Summary by Company 普源精电 (Puyuan Precision Electric) - The company announced a delay in the "Shanghai R&D Center Construction Project" to April 2026 due to changes in the implementation method and the late completion of the new building [4][5]. 高华科技 (Gaohua Technology) - The "Gaohua R&D Capability Construction Project" has been postponed to June 30, 2026, due to tight operating funds before the IPO and the establishment of two new subsidiaries affecting the project timeline [6]. 莱伯泰科 (Leibotai Technology) - The timeline for the "Trace and Ultra-trace Element Analysis ICP-MS and Online Analysis System Production and R&D Project" has been extended to September 2026, influenced by evolving user demands and market conditions [7][8]. 迈拓股份 (Maituo Co., Ltd.) - The "Ultrasonic Measuring Instrument Production Base Construction Project in Nanjing" is delayed until December 31, 2025, due to delays in obtaining construction permits and other unforeseen factors [9][10]. 智能自控 (Intelligent Control) - The company decided to extend the timeline for its fundraising projects due to changes in the macroeconomic environment and market conditions, affecting project completion [11]. 碧兴物联 (Bixing IoT) - The "Smart Ecological Environment Big Data Service Project" and "Smart Water Big Data Traceability Analysis Service Project" have been postponed to August 2026, with no changes to the project scope or funding [12][13]. 煜邦电力 (Yubang Electric) - The company has terminated certain sub-projects and extended the timeline for remaining projects to December 2026, citing increased competition and market conditions [14][15]. 天罡股份 (Tiangang Co., Ltd.) - The "IoT Smart Ultrasonic Measuring Instrument Industrialization Project" and "R&D Center Upgrade Construction Project" have been postponed to June 30, 2026, due to equipment procurement delays and project adjustments [17][18].

Core Viewpoint - Beijing Labtech Instrument Co., Ltd. is holding a half-year performance briefing on September 24, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in Q&A sessions [2][3]. Group 1: Meeting Details - The performance briefing is scheduled for September 24, 2025, from 16:00 to 17:00 [6]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible online [2][6]. - The format of the meeting will be an interactive online session, enabling real-time communication with investors [3][5]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date [5]. - A pre-collection of questions will be available from September 17 to September 23, 2025, allowing investors to submit inquiries via the website or email [5][6]. - The company will address commonly asked questions during the briefing [3][5]. Group 3: Attendees - Key attendees include Mr. Hu Ke, Chairman and General Manager, Ms. Yu Hao, Secretary of the Board and Financial Officer, and Ms. Yin Bitiao, Independent Director [4].

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-035 北京莱伯泰科仪器股份有限公司 关于召开 2025 年半年度业绩说明会的公告 投资者可于 2025 年 09 月 17 日 （星期三） 至 09 月 23 日 （星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqtzb@labtechgroup.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 北京莱伯泰科仪器股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 09 月 24 日（星期三） 16:00-17:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：202 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-034 北京莱伯泰科仪器股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 09 月 15 日 （二） 股东会召开的地点：北京市顺义区空港工业区 B 区安庆大街 6 号北京莱 伯泰科仪器股份有限公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 28 | | --- | --- | | 普通股股东人数 | 28 | | 2、出席会议的股东所持有的表决权数量 | 41,151,918 | | 普通股股东所持有表决权数量 | 41,151,918 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 61.6247 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于北京莱伯泰科仪器股份有限公司 2025 年第一次临时股东会的法律意见书 致：北京莱伯泰科仪器股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民 共和国公司法》（以下简称"《公司法》"）以及中国证券监督管理委员会颁布的 《上市公司股东会规则（2025修订）》（以下简称"《股东会规则》"）的规定， 北京市竞天公诚律师事务所（以下简称"本所"）指派律师对公司2025年第一次临 时股东会（以下简称"本次股东会"）进行现场见证，并就本次股东会的有关事宜 出具本法律意见书。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信 用原则，进行了充分的核查验证，保证本法律意见书所认定的事实真实、准确、 完整，所发表的结论性意见合法、准确 ...

Summary of the Conference Call on the Scientific Instrument Industry Industry Overview - The scientific instrument industry in China is experiencing growth driven by increasing R&D expenditure, which reached 3.34 trillion yuan in 2023, a year-on-year increase of 8.4% [1][3] - The market for scientific instruments, including mass spectrometry, chromatography, and spectroscopy, exceeds 50 billion yuan, but remains highly dependent on imports, with mass spectrometry and chromatography import rates at 90% and 88% respectively [1][3] Key Insights - The proportion of R&D expenditure to GDP in China has been steadily increasing, reaching 2.6% in 2023, indicating stronger governmental support for technological innovation and a rising demand for high-end scientific instruments [1][3][6] - The mass spectrometry market in China is approaching 20 billion yuan, with a growth rate of approximately 15%, but it is still heavily reliant on imports, particularly from the U.S., which maintains a stable market share of around 20% [1][8][10] - The scientific service industry encompasses research institutions, universities, and innovative enterprises, providing high-tech solutions and third-party testing services, characterized by high technological content and talent concentration [4][5] Market Dynamics - The scientific instrument supply chain consists of three main segments: 1. Reagent and consumables companies (e.g., Titan Technology, Aladdin) 2. Scientific instrument manufacturers (e.g., Focused Photonics, Labtech) 3. Third-party testing service providers (e.g., Huace Testing, Puni Testing) [6] - The increasing focus on domestic scientific instruments due to U.S.-China trade tensions is expected to enhance the market share of domestic manufacturers [3][10] Competitive Landscape - There is a significant gap between Chinese scientific service companies and their overseas counterparts, with leading foreign firms like Merck and Agilent having market capitalizations exceeding 100 billion USD, while only five Chinese companies exceed 10 billion USD in market cap [2][11] - The average gross margin for Chinese companies is 46%, lower than the 52% average for foreign companies, indicating potential for profit margin improvement as domestic companies scale up [11][12] Future Outlook - As penetration rates increase and costs decrease, the gross margins of Chinese scientific service companies are expected to improve, potentially leading to the emergence of new domestic leaders in the industry [12] - Investment recommendations include focusing on companies engaged in R&D and the scientific instrument sector, such as Focused Photonics, Wuyi Technology, and Labtech, which are in the early stages but show significant growth potential [13]